SCHEMBL1321695

SCHEMBL1321695

N#Cc1cccc2cc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3)ccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC22A12 Q96S37 4/20 0.50
▸ MAPT P10636 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ PGR P06401 1/20 0.46
▸ CYP3A4 P08684 4/20 0.45
▸ IMPDH2 P12268 1/20 0.45
▸ HSP90AA1 P07900 1/20 0.44
▸ HSP90AB1 P08238 1/20 0.44
▸ CYP2D6 P10635 2/20 0.44
▸ PSEN1 P49768 1/20 0.44
▸ PSEN2 P49810 1/20 0.44
▸ APH1B Q8WW43 1/20 0.44
▸ NCSTN Q92542 1/20 0.44
▸ APH1A Q96BI3 1/20 0.44
▸ PSENEN Q9NZ42 1/20 0.44
▸ CYP19A1 P11511 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ GPR119 Q8TDV5 2/20 0.43
▸ ACLY P53396 1/20 0.43
▸ BRD4 O60885 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13658722 0.81 CYP2C9 (0.60) PGRCYP3A4HSP90AA1HSP90AB1CYP2D6
SCHEMBL15010735 0.81 CYP2C9 (0.51) MAPTNPSR1PGRIMPDH2PKM
SCHEMBL1319869 0.78 ACLY (0.45) SLC22A12MAPTNPSR1ACLY
SCHEMBL1110309 0.78 ACLY (0.49) PGRCYP3A4HSP90AA1HSP90AB1CYP2D6
SCHEMBL1110258 0.78 ACLY (0.58) PGRACLY
SCHEMBL1110383 0.77 ACLY (0.48) PGRCYP3A4HSP90AA1HSP90AB1CYP2D6
SCHEMBL1318489 0.76 BRPF1 (0.50) PGRCYP3A4CYP2D6PSEN1PSEN2
SCHEMBL29561686 0.76 MAPT (0.55) SLC22A12MAPTNPSR1PGRCYP3A4
SCHEMBL1319712 0.75 BRPF1 (0.49) PGRCYP3A4CYP2D6PSEN1PSEN2
SCHEMBL1320440 0.75 ACLY (0.49) PGRCYP3A4HSP90AA1HSP90AB1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 — — US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 — — US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 SLC22A12 2297/4885MAPT 4383/4885NPSR1 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback